Final Survival Follow-Up and Translational Associations Using Interval Indirect Immunization with Oregovomab (O) and Poly ICLC in Patients (pts) with Recurrent Platinum-Resistant Ovarian Cancer (PROC).
JOURNAL OF CLINICAL ONCOLOGY（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要